Clinical Decision Support for Oncology

PredictRx™ provides phenotypic drug sensitivity testing on patient-derived cancer cells to support treatment selection in challenging clinical scenarios.

Performance Metrics

Positive Predictive Value
>90%

Negative Predictive Value
100%

Drugs Tested
~60

Turnaround Time
4-5 wks

Clinical Evidence

PredictRx™ is based on technology originally developed by Imagen Therapeutics and validated through multiple clinical studies. The platform has been refined over several years of research collaboration with leading UK cancer centres.

Solid Tumour Validation Study

39 patients with various solid tumours

89.5%
Positive Predictive Value

100%
Negative Predictive Value

17 positive predictions confirmed, 20 cases with no positive response identified, 2 false positives. Data on file, Dominion Biotech.

Royal Marsden Collaboration

Institute of Cancer Research study

71
Metastatic patients screened

96%
Genetic similarity to original tumour

3D in-vitro assay drug screening demonstrated high concordance with clinical outcomes.

Key Findings

Clinical correlation studies have demonstrated that PredictRx™ results align with patient outcomes in the majority of cases. The platform shows particular strength in identifying treatments unlikely to be effective (100% NPV), which can help to avoid futile therapies and associated toxicities.

In several cases, PredictRx™ identified effective treatments that would not have been predicted based on genomic profiling alone, highlighting the value of phenotypic testing as a complement to molecular diagnostics.

Methodology

PredictRx™ employs a proprietary phenotypic drug sensitivity assay using low-passage patient-derived cells to maintain clinically relevant characteristics.

Technical Overview

Sample Reception: Fresh tumour tissue is received and processed within 1-2 days of collection using a proprietary culture system.
Cell Isolation and Culture: Tumour is enzymatically dissociated into single cells and cultured in selective media designed to preferentially support cancer cell growth while minimising normal cell contamination. Culture period: 3-4 weeks to achieve sufficient cell numbers (~2 million cells).
Drug Screening: Cells are exposed to approximately 60 oncology drugs at 4 different concentrations each, generating dose-response curves for each compound. Assay duration: 72 hours.
Analysis: Cell death is quantified using high-content imaging with nuclear staining. A computerised microscope scans all wells and measures relative cell death for each treatment.
Computational Analysis: Results are analysed using proprietary machine learning algorithms and compared against a database of >150,000 drug-response data points from previous patients.
Report Generation: Treatments are ranked and categorised based on relative efficacy. A clinical report is generated highlighting predicted effective and ineffective options.

Quality Control

Each assay includes positive and negative controls. Cell viability and purity are assessed before screening. Only samples meeting quality thresholds proceed to testing.

Current Drug Panel

PredictRx™ tests approximately 60 oncology agents across multiple drug classes. The panel is regularly updated to reflect current clinical practice.

Chemotherapies

5-Fluorouracil
Bleomycin
Carmustine
Cisplatin
Cyclophosphamide
Dacarbazine
Docetaxel
Doxorubicin

Eribulin
Etoposide
Gemcitabine
Irinotecan
Lomustine
Melphalan
Methotrexate
Mitomycin C

Mitoxantrone
Oxaliplatin
Paclitaxel
Temozolomide
Teniposide
Topotecan
Vincristine
Vinorelbine

Targeted Therapies

Afatinib
Axitinib
Bortezomib
Bosutinib
Cabozantinib
Carfilzomib
Cediranib
Cladribine
Clofarabine
Crizotinib
Dabrafenib
Dasatinib
Epothilone B

Erlotinib
Everolimus
Ganetespib
Gefitinib
Herceptin
Imatinib
Lapatinib
Nilotinib
Olaparib
Osimertinib
Palbociclib
Pazopanib

Ponatinib
Rapamycin
Regorafenib
Ribociclib
Ruxolitinib
Sorafenib
Sunitinib
Trametinib
Vandetanib
Vemurafenib
Vismodegib
Vorinostat

Current Limitations

PredictRx™ does not currently test the following drug classes:

Immunotherapies: Checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4) and other immunomodulatory agents
Prodrugs: Agents requiring hepatic metabolism (e.g., capecitabine/Xeloda)
Anti-angiogenic monoclonal antibodies: Such as bevacizumab (Avastin)
CAR-T and other cell therapies: Require immune system context not present in vitro

Note: The assay tests direct cytotoxic effects on cancer cells and cannot model immune-mediated mechanisms or drug metabolism that occurs in vivo. We are actively developing capabilities to expand our testing into immunotherapy and CAR-T cell therapy areas. If you have specific therapeutic options you’d like us to evaluate, please contact us to discuss potential collaboration.

Sample Requirements & Logistics

Acceptable Sample Types

Solid Tissue: Minimum 1cm³ fresh tumour (preferred)
Core Biopsies: 4x 10mm cores (18G needle)
Ascites: 250ml minimum volume
Pleural Effusion: 250ml minimum volume

Post-treatment samples preferred for treatment-resistant disease. Treatment-naive samples acceptable for rare/undefined cancers.

Sample Handling

Fresh tissue required (no formalin fixation)
Store in provided NanoCool preservation kit
Ship via medical courier within 92 hours of collection
Maintain at room temperature (do not freeze)
Include completed clinical information form

Success Rates by Sample Type

Fresh surgical specimens: Highest success rate
Core biopsies: Variable (tissue type dependent)
Effusions: Good success for carcinomatosis
Post-radiation tissue: Lower viability

Not all samples yield viable cells. Success varies by tumour type, treatment history, and sample quality.

Turnaround Time

Sample to Lab: 1-2 days (courier)
Cell Culture: 3-4 weeks
Drug Screening: 3 days
Analysis & Report: 1-2 days
Total: Final report delivered within 4-5 weeks from sample receipt

Optimal Clinical Scenarios

PredictRx™ provides greatest clinical utility in specific situations where treatment decisions are challenging.

Rare Tumours

Undefined Standard of Care

When facing cancers with limited clinical trial data or established treatment algorithms, PredictRx™ can help identify potentially effective options from the broader oncology pharmacopeia.

Example: Rare sarcoma subtypes, unusual presentations of common cancers

Aggressive Disease

Treatment Optimization

For rapidly progressive disease where selecting the most effective treatment quickly is critical, PredictRx™ can help prioritise options within 3-4 weeks.

Example: High-grade neuroendocrine tumours, rapidly progressive metastatic disease

Refractory Disease

Treatment-Resistant Cancer

When cancer has progressed through standard therapies, PredictRx™ tests using treatment-resistant cells to identify remaining effective options.

Example: Platinum-resistant ovarian cancer, multiply-relapsed leukaemia

Complementary to Genomic Testing

PredictRx™ provides orthogonal information to next-generation sequencing and other molecular diagnostics. While genomics identifies potential drug targets based on mutations, PredictRx™ demonstrates actual drug sensitivity of the living cancer cells, sometimes revealing effective treatments not predicted by genomic analysis.

Several case studies have shown PredictRx™ correctly identifying EGFR inhibitor sensitivity in NSCLC later confirmed to have EGFR mutations, as well as predicting lack of EGFR sensitivity in EGFR wild-type cases — demonstrating potential utility as a functional biomarker.

How to Request PredictRx™ Testing

If you have a patient who might benefit from PredictRx™ testing, we’re here to support you through the process.

Request Information